Literature DB >> 8392979

Protein phosphatases limit tumor motility.

M R Young1, Y Lozano, A Djorjevic, G D Maier.   

Abstract

Elevators of cAMP, such as prostaglandin E2 (PGE2), activate protein kinase A (PKA) and induce PKA-stimulated motility and metastasis by metastatic Lewis lung carcinoma cells (LLC-LN7). Non-metastatic LLC (LLC-C8) are unresponsive to cAMP elevation even though they are not deficient in the PKA enzymes. To determine whether this PKA unresponsiveness might be due to increased dephosphorylation by serine/threonine protein phosphatases (PP-1/2A) within non-metastatic LLC-C8, the effects of the PP-1/2A inhibitor okadaic acid on the migration and invasion by non-metastatic LLC-C8 cells was measured. Okadaic acid stimulated motility of non-metastatic LLC-C8 cells to a level that was comparable to that of metastatic LLC-LN7 cells. PGE2 further increased the motility of the non-metastatic LLC-C8 cells when okadaic acid was present, although not in the absence of okadaic acid. The stimulation of motility by okadaic acid was diminished when PKA activity was inhibited. Dose-response studies with concentrations of okadaic acid that selectively inhibited PP-2A or both PP-2A and PP-1 showed a progressive increase in migration of non-metastatic LLC-C8 cells, suggesting that both PP-1 and PP-2A limit their motility. By contrast, metastatic LLC-LN7 cells were more motile than were non-metastatic LLC-C8 cells, but this motility was only marginally affected by okadaic acid. Comparisons of the levels of PP-1/2A enzyme activities in the LLC variants showed more activity in non-metastatic LLC-C8 than in metastatic LLC-LN7 cells. The identity of the PP whose activity was increased in the non-metastatic LLC-C8 was assessed by using okadaic acid, which selectively inhibits PP-2A activity at low concentrations and PP-1 and PP-2A at high concentrations, and calyculin A, which inhibits PP-2A at a similar concentration to that affected by okadaic acid but is more potent at inhibiting PP-1. The inhibition of PP activities by okadaic acid and by calyculin A showed a pattern which suggested the presence both of PP-1 and of PP-2A in non-metastatic LLC-C8 cells, but the presence of PP-1 and a reduction in PP-2A in metastatic LLC-LN7 cells. The sum of these data suggests that PKA-stimulated motility is restricted both by PP-1 and by PP-2A in non-metastatic LLC, and that a deficiency in this restriction results in increased migration and invasion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392979     DOI: 10.1002/ijc.2910540629

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation.

Authors:  A Ito; T R Kataoka; M Watanabe; K Nishiyama; Y Mazaki; H Sabe; Y Kitamura; H Nojima
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

2.  Inhibition of tumor invasiveness by 1alpha,25-dihydroxyvitamin D3 coupled to a decline in protein kinase A activity and an increase in cytoskeletal organization.

Authors:  M R Young; Y Lozano
Journal:  Clin Exp Metastasis       Date:  1997-03       Impact factor: 5.150

3.  Protein kinase A regulates Lewis lung carcinoma adherence to extracellular matrix components and spontaneous metastasis.

Authors:  G D Maier; K Vellody; J Meisinger; A Djordjevic; Y Lozano; M R Young
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

Review 4.  Eicosanoids and the immunology of cancer.

Authors:  M R Young
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

5.  Protein phosphatase-2A modulates the serine and tyrosine phosphorylation of paxillin in Lewis lung carcinoma tumor variants.

Authors:  Jodi L Jackson; M Rita I Young
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

6.  Dynamic regulation of extracellular signal-regulated kinase (ERK) by protein phosphatase 2A regulatory subunit B56γ1 in nuclei induces cell migration.

Authors:  Ei Kawahara; Shiori Maenaka; Eri Shimada; Yoshihiro Nishimura; Hiroshi Sakurai
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.